The pharma company has a number of positives working in its favour
Cadila Healthcare has a very rare business model among Indian pharmaceutical companies. Its revenue mix is composed of CRAM (contract research and manufacturing) and formulation sales. Approximately 20 per cent of its profits are derived from the CRAM space and rest of the 80 per cent comes through its formulations and API businesses. In the domestic market it is present in both ethical and over-the-counter (OTC) segments.
This article was originally published on May 15, 2009.
Gold hits record high. Should you still buy?
3 min read•By Ujjal Das
New episodes every Friday
The gambling instinct
When investing morphs into betting, everyone loses except the house
Other Episodes
'Earnings will make a comeback in the second half of 2025'
Bhavesh Jain of Edelweiss on why the Indian market will recover only in the later stages of 2025
The investor in the mirror
Why human emotions can be our own worst enemy
Is gold a relic or a refuge?
Even skeptics may need to reconsider gold's role in a changing global financial order
Winning by doing nothing
Market turmoil from tariff wars offers a masterclass in investor psychology
Widely read:
